PART I Overview We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Our Portfolio Our portfolio is principally focused on our lead product candidate, Niyad (nafamostat mesylate), for use as a regional anticoagulant during continuous renal replacement therapy, or CRRT. In addition, we may develop LTX-608, a nafamostat formulation for direct IV infusion for one or more of the following indicati...
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001437749-26-009387 | EDGAR | 66K words |
| 2025-03-31 | 2024-12-31 | 0001437749-25-010250 | EDGAR | — |
| 2024-03-06 | 2023-12-31 | 0001437749-24-006849 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001437749-23-008737 | EDGAR | — |
| 2022-03-10 | 2021-12-31 | 0001437749-22-005888 | EDGAR | — |
| 2021-03-15 | 2020-12-31 | 0001437749-21-006074 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001437749-20-005304 | EDGAR | — |
| 2019-03-07 | 2018-12-31 | 0001437749-19-004353 | EDGAR | — |
| 2018-03-09 | 2017-12-31 | 0001437749-18-004222 | EDGAR | — |
| 2017-03-03 | 2016-12-31 | 0001437749-17-003702 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001437749-25-034499 | EDGAR | 42K words |
| 2025-08-14 | 2025-06-30 | 0001437749-25-027002 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001437749-25-016898 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001437749-24-034965 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001437749-24-026801 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001437749-24-016694 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001437749-23-031742 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001437749-23-023124 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001437749-23-013658 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001437749-22-027307 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001437749-22-020168 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001437749-22-012491 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-23 | 0001437749-26-009299 | EDGAR | 3K words |
| 2026-03-16 | 0001437749-26-008318 | EDGAR | — |
| 2026-03-13 | 0001437749-26-008217 | EDGAR | — |
| 2025-11-12 | 0001437749-25-034446 | EDGAR | — |
| 2025-10-24 | 0001437749-25-031731 | EDGAR | — |
| 2025-10-22 | 0001437749-25-031468 | EDGAR | — |
| 2025-10-16 | 0001437749-25-031162 | EDGAR | — |
| 2025-09-10 | 0001437749-25-028787 | EDGAR | — |
| 2025-08-14 | 0001437749-25-026938 | EDGAR | — |
| 2025-06-05 | 0001437749-25-019574 | EDGAR | — |
352 total filings indexed. 320 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001427925 |
| Ticker | TLPH |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.talphera.com |
| Listed | 2011-02-11 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/TLPH (~200 tokens, structured JSON with cryptographic provenance)